

Anke H Maitland-Van Der Zee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592950/publications.pdf>

Version: 2024-02-01

280
papers

12,346
citations

50276

46
h-index

33894

99
g-index

296
all docs

296
docs citations

296
times ranked

17920
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries. <i>Pediatric Nephrology</i> , 2023, 38, 593-604.	1.7	4
2	Mapping atopic dermatitis and anti-IL-22 response signatures to type 2 low severe neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 89-101.	2.9	22
3	Targeted exhaled breath analysis for detection of <i>Pseudomonas aeruginosa</i> in cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2022, 21, e28-e34.	0.7	17
4	Comparison of microbial composition of cough swabs and sputum for pathogen detection in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 52-60.	0.7	6
5	Prediction of asthma in early preschool wheezing by electronic nose analysis. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	2.6	3
6	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. <i>European Respiratory Journal</i> , 2022, 59, 2102603.	6.7	11
7	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	3
8	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4297-4310.	2.4	12
9	Primary ciliary dyskinesia in Volendam: Diagnostic and phenotypic features in patients with a <i>CCDC114</i> mutation. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2022, 190, 89-101.	1.6	5
10	Pulmonary Oxygen Toxicity Through Exhaled Breath Markers After Hyperbaric Oxygen Treatment Table 6. <i>Frontiers in Physiology</i> , 2022, 13, .	2.8	8
11	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. <i>European Respiratory Journal</i> , 2021, 57, 2002042.	6.7	28
12	Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 123-134.	2.9	51
13	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	4.7	31
14	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 735-750.	5.7	83
15	AsthmaMap: An interactive knowledge repository for mechanisms of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 853-856.	2.9	6
16	Early-life antibiotic use and risk of attention-deficit hyperactivity disorder and autism spectrum disorder: results of a discordant twin study. <i>International Journal of Epidemiology</i> , 2021, 50, 475-484.	1.9	20
17	Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1238-1243.	5.7	11
18	Higher prescription of antidepressants and/or anxiolytics among chronic obstructive pulmonary disease patients. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662096169.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Nonadherence to inhaled corticosteroids: A characteristic of the pediatric obese asthma phenotype?. <i>Pediatric Pulmonology</i> , 2021, 56, 948-956.	2.0	3
20	Association of endopeptidases, involved in SARS-CoV-2 infection, with microbial aggravation in sputum of severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1917-1921.	5.7	3
21	Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7.	14.3	134
22	The Influence of Smoking Status on Exhaled Breath Profiles in Asthma and COPD Patients. <i>Molecules</i> , 2021, 26, 1357.	3.8	7
23	Increased day-to-day fluctuations in exhaled breath profiles after a rhinovirus challenge in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2488-2499.	5.7	9
24	SHARP: enabling generation of real-world evidence on a pan-European scale to improve the lives of individuals with severe asthma. <i>ERJ Open Research</i> , 2021, 7, 00064-2021.	2.6	10
25	Genome-wide association studies of exacerbations in children using long-acting beta ₂ -agonists. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1197-1207.	2.6	13
26	Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 985-992.	1.9	1
27	The Impact of Short-Term Exposure to Air Pollution on the Exhaled Breath of Healthy Adults. <i>Sensors</i> , 2021, 21, 2518.	3.8	5
28	A System Pharmacology Multi-Omics Approach toward Uncontrolled Pediatric Asthma. <i>Journal of Personalized Medicine</i> , 2021, 11, 484.	2.5	11
29	Treating severe asthma: Targeting the IL-5 pathway. <i>Clinical and Experimental Allergy</i> , 2021, 51, 992-1005.	2.9	30
30	Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103312.	4.4	8
31	Biologicals in childhood severe asthma: the European PERMEABLE survey on the <i>status quo</i> . <i>ERJ Open Research</i> , 2021, 7, 00143-2021.	2.6	9
32	<i>ADRB2</i> haplotypes and asthma exacerbations in children and young adults: An individual participant data meta-analysis. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1157-1171.	2.9	6
33	Identification of <i>ROBO2</i> as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma. <i>Journal of Personalized Medicine</i> , 2021, 11, 733.	2.5	6
34	Associations between macrovascular and renal microvascular dysfunction in type 2 diabetes and non-diabetes: the HELIUS study. <i>Microvascular Research</i> , 2021, 136, 104162.	2.5	4
35	Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study. <i>EClinicalMedicine</i> , 2021, 38, 101012.	7.1	6
36	Alterations to the urinary metabolome following semi-controlled short exposures to ultrafine particles at a major airport. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 237, 113803.	4.3	2

#	ARTICLE	IF	CITATIONS
37	Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 555-563.	2.0	10
38	Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study. <i>ERJ Open Research</i> , 2021, 7, 00457-2021.	2.6	13
39	LTA4H rs2660845 association with montelukast response in early and late-onset asthma. <i>PLoS ONE</i> , 2021, 16, e0257396.	2.5	6
40	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 957-968.	10.7	83
41	The potential role of SP-D as an early biomarker of severity of asthma. <i>Journal of Breath Research</i> , 2021, 15, 041001.	3.0	3
42	Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use. <i>European Respiratory Journal</i> , 2021, 57, 2003388.	6.7	17
43	Associations of Serum Uric Acid Levels With Macrovascular and Renal Microvascular Dysfunction Among Individuals From Sub-Saharan Africa. <i>JAMA Network Open</i> , 2021, 4, e2128985.	5.9	8
44	Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy. <i>ERJ Open Research</i> , 2021, 7, 00381-2021.	2.6	5
45	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	2.5	5
46	Exhaled Metabolite Patterns to Identify Recent Asthma Exacerbations. <i>Metabolites</i> , 2021, 11, 872.	2.9	2
47	Exhaled volatile organic compounds as markers for medication use in asthma. <i>European Respiratory Journal</i> , 2020, 55, 1900544.	6.7	27
48	Higher prevalence of peripheral arterial disease in Ghana compared to Ghanaian migrants in Europe: The RODAM study. <i>International Journal of Cardiology</i> , 2020, 305, 127-134.	1.7	8
49	International Severe Asthma Registry. <i>Chest</i> , 2020, 157, 805-814.	0.8	38
50	Precision medicine in severe pediatric asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 77-83.	2.6	11
51	<i>IL1RL1</i> gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 984-989.	5.7	14
52	C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101870.	2.6	1
53	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
54	Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 975.	3.5	4

#	ARTICLE	IF	CITATIONS
55	Association between C reactive protein and microvascular and macrovascular dysfunction in sub-Saharan Africans with and without diabetes: the RODAM study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001235.	2.8	9
56	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1045-1055.	2.9	22
57	Precision Medicine in Neonates: Future Perspectives for the Lung. <i>Frontiers in Pediatrics</i> , 2020, 8, 586061.	1.9	10
58	Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000767.	2.8	8
59	International severe asthma registry (ISAR): protocol for a global registry. <i>BMC Medical Research Methodology</i> , 2020, 20, 212.	3.1	29
60	The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6627.	4.1	25
61	Bronchiectasis in Severe Asthma: Does It Make a Difference?. <i>Respiration</i> , 2020, 99, 1136-1144.	2.6	10
62	Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. <i>Clinical and Translational Allergy</i> , 2020, 10, 58.	3.2	56
63	Effects of short-term exposures to ultrafine particles near an airport in healthy subjects. <i>Environment International</i> , 2020, 141, 105779.	10.0	36
64	Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2999-3008.e1.	3.8	17
65	Exome Sequencing Reveals Common and Rare Variants in <i>ACE</i> Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1195-1202.	4.7	18
66	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	3.2	97
67	Cross-sectional biomarker comparisons in asthma monitoring using a longitudinal design: The eNose premise. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2690-2693.	5.7	8
68	Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study. <i>European Respiratory Journal</i> , 2020, 55, 1902021.	6.7	32
69	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1150-1164.	2.4	42
70	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. <i>Pharmacogenomics Journal</i> , 2020, 20, 770-783.	2.0	22
71	Childhood asthma in the new omics era: challenges and perspectives. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 155-161.	2.3	26
72	Omics for the future in asthma. <i>Seminars in Immunopathology</i> , 2020, 42, 111-126.	6.1	29

#	ARTICLE	IF	CITATIONS
73	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. <i>Pharmacogenomics Journal</i> , 2020, 20, 621-628.	2.0	10
74	Characteristics and treatment regimens across ERS SHARP severe asthma registries. <i>European Respiratory Journal</i> , 2020, 55, 1901163.	6.7	56
75	Identification of recent exacerbations in COPD patients by electronic nose. <i>ERJ Open Research</i> , 2020, 6, 00307-2020.	2.6	3
76	Genomics and Pharmacogenomics of Severe Childhood Asthma. , 2020, , 313-341.		0
77	Assessment of pulmonary oxygen toxicity in special operations forces divers under operational circumstances using exhaled breath analysis. <i>Diving and Hyperbaric Medicine</i> , 2020, 50, 2-8.	0.5	5
78	Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis. <i>Frontiers in Genetics</i> , 2020, 11, 570403.	2.3	1
79	FCER2 T2206C variant associated with FENO levels in asthmatic children using inhaled corticosteroids: The PACMAN study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1429-1436.	2.9	10
80	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. <i>PLoS ONE</i> , 2019, 14, e0218115.	2.5	18
81	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 240.	1.7	22
82	Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. <i>Annals of Oncology</i> , 2019, 30, 1660-1666.	1.2	63
83	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	4.7	58
84	Breathomics and treatable traits for chronic airway diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 94-100.	2.6	19
85	Genome-wide association study of inhaled corticosteroid response in admixed children with asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 789-798.	2.9	50
86	Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 152-159.	1.6	17
87	Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: The RODAM study. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 572-578.	2.3	25
88	The crosstalk between microbiome and asthma: Exploring associations and challenges. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1067-1086.	2.9	52
89	Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. <i>Genes</i> , 2019, 10, 364.	2.4	21
90	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	3.6	17

#	ARTICLE	IF	CITATIONS
91	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	3.6	22
92	What did we learn from multiple omics studies in asthma?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2129-2145.	5.7	29
93	Markers of Pulmonary Oxygen Toxicity in Hyperbaric Oxygen Therapy Using Exhaled Breath Analysis. <i>Frontiers in Physiology</i> , 2019, 10, 475.	2.8	13
94	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2019, 53, 1900217.	6.7	25
95	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	1.3	97
96	Precision medicine in childhood asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 141-147.	2.3	13
97	Detecting Pulmonary Oxygen Toxicity Using eNose Technology and Associations between Electronic Nose and Gas Chromatographyâ€“Mass Spectrometry Data. <i>Metabolites</i> , 2019, 9, 286.	2.9	4
98	Identification and prospective stability of electronic nose (eNose)â€“derived inflammatory phenotypes in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1811-1820.e7.	2.9	74
99	Genetic associations of the response to inhaled corticosteroids in asthma: a systematic review. <i>Clinical and Translational Allergy</i> , 2019, 9, 2.	3.2	39
100	Effect of <i>CYP4F2</i> , <i>VKORC1</i> , and <i>CYP2C9</i> in Influencing Coumarin Dose: A Singleâ€“Patient Data Metaâ€“Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	4.7	23
101	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	3.8	39
102	eNose breathprints as surrogate biomarkers for classifying asthma patients by atopy. , 2019, , .		1
103	Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1336-1342.	2.4	10
104	The use of pharmacogenomics, epigenomics, and transcriptomics to improve childhood asthma management: Where do we stand?. <i>Pediatric Pulmonology</i> , 2018, 53, 836-845.	2.0	23
105	Patterns of topical corticosteroids prescriptions in children with asthma. <i>Pediatric Dermatology</i> , 2018, 35, 378-383.	0.9	1
106	Biomarkers and asthma management: analysis and potential applications. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 96-108.	2.3	21
107	Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. <i>European Respiratory Journal</i> , 2018, 51, 1701817.	6.7	98
108	What do we need to transfer pharmacogenetics findings into the clinic?. <i>Pharmacogenomics</i> , 2018, 19, 589-592.	1.3	22

#	ARTICLE	IF	CITATIONS
109	Blood biomarkers in chronic airways diseases and their role in diagnosis and management. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 361-374.	2.5	10
110	The association between a genetic risk score for allergy and the risk of developing allergies in childhood—Results of the WHISTLER cohort. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 72-77.	2.6	8
111	Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 776-785.	2.4	31
112	Early-life antibiotic exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 971-986.	5.7	90
113	Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 116-124.	3.8	6
114	Treatment response heterogeneity in asthma: the role of genetic variation. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 55-65.	2.5	31
115	Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1191-1199.	1.9	17
116	Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2018, 9, 1111.	3.5	35
117	Effects of age and genetic variations in <i>VKORC1</i> , <i>CYP2C9</i> and <i>CYP3A4</i> on the phenprocoumon dose in pediatric patients. <i>Pharmacogenomics</i> , 2018, 19, 1195-1202.	1.3	2
118	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. <i>Drug and Alcohol Dependence</i> , 2018, 188, 94-101.	3.2	10
119	Variants in genes coding for glutathione S-transferases and asthma outcomes in children. <i>Pharmacogenomics</i> , 2018, 19, 707-713.	1.3	10
120	Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2365-2372.	2.4	24
121	The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1732-1742.	3.8	8
122	AsthmaMap: An expert-driven computational representation of disease mechanisms. <i>Clinical and Experimental Allergy</i> , 2018, 48, 916-918.	2.9	21
123	Pharmacogenetics of inhaled long-acting beta ₂ -agonists in asthma: A systematic review. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 705-714.	2.6	34
124	17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2083-2088.	5.7	22
125	AddIT Editorial comment—challenges in medication treatment of renal and cardiovascular diseases and risk factors in adolescents with type 1 diabetes. <i>Annals of Translational Medicine</i> , 2018, 6, 193-193.	1.7	1
126	Dosing algorithms for vitamin K antagonists across <i>VKORC1</i> and <i>CYP2C9</i> genotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 465-472.	3.8	8

#	ARTICLE	IF	CITATIONS
127	The need for precision medicine clinical trials in childhood asthma: rationale and design of the PUFFIN trial. <i>Pharmacogenomics</i> , 2017, 18, 393-401.	1.3	19
128	Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1402-1404.	5.6	99
129	Early life antibiotic use and the risk of asthma and asthma exacerbations in children. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 430-437.	2.6	77
130	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 97-105.	11.4	298
131	Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 112-119.	1.5	16
132	Atopic dermatitis characteristics and medication-use patterns in school-age children with AD and asthma symptoms. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 503-508.	1.3	1
133	Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study. <i>Journal of Human Hypertension</i> , 2017, 31, 537-544.	2.2	5
134	Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review. <i>Clinical and Experimental Allergy</i> , 2017, 47, 271-293.	2.9	36
135	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	1.3	174
136	A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. <i>Pharmacogenomics</i> , 2017, 18, 23-34.	1.3	10
137	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 454-464.	3.8	4
138	Breathomics from exhaled volatile organic compounds in pediatric asthma. <i>Pediatric Pulmonology</i> , 2017, 52, 1616-1627.	2.0	78
139	Impact of Selection Bias on Estimation of Subsequent Event Risk. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	28
140	Adult derived genetic blood pressure scores and blood pressure measured in different body postures in young children. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 320-327.	1.8	7
141	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. <i>Pharmacogenomics</i> , 2017, 18, 1143-1153.	1.3	5
142	Breastfeeding is associated with a decreased risk of childhood asthma exacerbations later in life. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 649-654.	2.6	22
143	Asthma treatment patterns in Dutch children using medication dispensing data. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 606-608.	2.6	2
144	CKMGl _u 83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	5

#	ARTICLE	IF	CITATIONS
145	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. <i>Pharmacogenomics</i> , 2017, 18, 931-943.	1.3	30
146	Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. <i>Pharmacogenomics Journal</i> , 2017, 17, 386-392.	2.0	56
147	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017, 38, 3569-3575.	2.2	41
148	Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 183-190.	0.6	2
149	Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. <i>Pediatric Diabetes</i> , 2016, 17, 433-440.	2.9	6
150	Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic Testing. <i>Annals of Internal Medicine</i> , 2016, 164, 513.	3.9	80
151	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. <i>Pharmacogenomics</i> , 2016, 17, 583-591.	1.3	9
152	Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. <i>Paediatric Drugs</i> , 2016, 18, 251-260.	3.1	33
153	Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. <i>European Respiratory Journal</i> , 2016, 48, 1063-1073.	6.7	89
154	Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 21-28.	1.9	14
155	Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1647-1659.	2.4	31
156	Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes. <i>Pediatric Pulmonology</i> , 2016, 51, 1113-1121.	2.0	11
157	High incidence of oral corticosteroids prescriptions in children with asthma in early childhood. <i>Journal of Asthma</i> , 2016, 53, 1012-1017.	1.7	13
158	Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. <i>Pharmacogenomics Journal</i> , 2016, 16, 478-484.	2.0	27
159	Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. <i>International Journal of Epidemiology</i> , 2016, 45, 1927-1937.	1.9	94
160	Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2489-2497.	3.3	20
161	Seventeen years of statin pharmacogenetics: a systematic review. <i>Pharmacogenomics</i> , 2016, 17, 163-180.	1.3	52
162	Childhood asthma exacerbations and the Arg16 Î²2-receptor polymorphism: A meta-analysis stratified by treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 107-113.e5.	2.9	80

#	ARTICLE	IF	CITATIONS
163	A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. <i>Pharmacogenomics Journal</i> , 2016, 16, 231-237.	2.0	47
164	Genetic variation in uncontrolled childhood asthma despite ICS treatment. <i>Pharmacogenomics Journal</i> , 2016, 16, 158-163.	2.0	16
165	Asthmatic children that are uncontrolled despite inhaled corticosteroids have a distinct breathprint (the pacman2 study). <i>Clinical and Translational Allergy</i> , 2015, 5, O6.	3.2	1
166	Characteristics and severity of asthma in children with and without atopic conditions: a cross-sectional study. <i>BMC Pediatrics</i> , 2015, 15, 172.	1.7	25
167	Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0136324.	2.5	25
168	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 768-777.	3.4	33
169	<i>rs11313</i> polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1051-1059.	2.9	19
170	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 69-75.	1.7	28
171	Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density. <i>Osteoporosis International</i> , 2015, 26, 2019-2027.	3.1	11
172	Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. <i>Pharmacogenomics</i> , 2015, 16, 101-114.	1.3	9
173	Genotype-guided coumarin dosing: where are we now and where do we need to go next?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 509-522.	3.3	4
174	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. <i>Thrombosis Research</i> , 2015, 136, 94-100.	1.7	2
175	Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1095-1103.	2.1	16
176	Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. <i>International Journal of Cardiology</i> , 2015, 201, 644-645.	1.7	6
177	Pharmacogenetics of Coumarin Anticoagulant Therapy. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 307-328.	0.6	2
178	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet</i> , 2015, 385, 351-361.	13.7	562
179	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. <i>European Heart Journal</i> , 2014, 35, 3250-3257.	2.2	81
180	Phenotype Standardization for Statin-Induced Myotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 470-476.	4.7	166

#	ARTICLE	IF	CITATIONS
181	Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 451-462.	2.2	39
182	Application of routine electronic health record databases for pharmacogenetic research. <i>Journal of Internal Medicine</i> , 2014, 275, 590-604.	6.0	6
183	No association between <i>CYP3A4</i> and statin effectiveness in reducing the risk for myocardial infarction. <i>Pharmacogenomics</i> , 2014, 15, 1471-1477.	1.3	10
184	The <i>SLCO1B1</i> c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 43-51.	1.5	42
185	Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 626-641.	2.4	113
186	Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 314-320.	4.7	12
187	Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 422-429.	2.4	8
188	Evaluation of the effects of single-nucleotide polymorphisms in <i>CYP3A4</i> and <i>CYP4F2</i> on stable phenprocoumon and acenocoumarol maintenance doses: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1197-1198.	3.8	0
189	Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 15-17.	4.7	15
190	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. <i>BMJ</i> , The, 2014, 349, g4164-g4164.	6.0	528
191	Pharmacogenetic analysis of <i>GLCC11</i> in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. <i>Pharmacogenomics</i> , 2014, 15, 799-806.	1.3	28
192	Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 477-481.	4.7	15
193	The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Initiation?. <i>Current Molecular Medicine</i> , 2014, 14, 841-848.	1.3	5
194	From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 369-375.	2.1	16
195	Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study. <i>BMC Pediatrics</i> , 2013, 13, 94.	1.7	2
196	A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. <i>New England Journal of Medicine</i> , 2013, 369, 2304-2312.	27.0	210
197	A Randomized Trial of Genotype-Guided Dosing of Warfarin. <i>New England Journal of Medicine</i> , 2013, 369, 2294-2303.	27.0	735
198	Secretory Phospholipase A2-IIA and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1966-1976.	2.8	115

#	ARTICLE	IF	CITATIONS
199	Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2013, 14, 249-260.	1.3	52
200	Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 518-525.	1.5	23
201	Costâ€“effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. <i>Pharmacogenomics</i> , 2013, 14, 869-883.	1.3	17
202	Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. <i>Pharmacogenomics Journal</i> , 2013, 13, 318-324.	2.0	7
203	<i>ADRB2</i> Arg16 and the need for collaboration in childhood asthma pharmacogenomics. <i>Pharmacogenomics</i> , 2013, 14, 1937-1939.	1.3	9
204	Arg16 <i>ADRB2</i> genotype increases the risk of asthma exacerbation in children with a reported use of long-acting $I^2 ₂$ -agonists: results of the pacman cohort. <i>Pharmacogenomics</i> , 2013, 14, 1965-1971.	1.3	48
205	Clinical utility of asthma biomarkers: from bench to bedside. <i>Biologics: Targets and Therapy</i> , 2013, 7, 199.	3.2	64
206	Evaluation of the effect of genetic variations in <i>GATA-4</i> on the phenprocoumon and acenocoumarol maintenance dose. <i>Pharmacogenomics</i> , 2012, 13, 1917-1923.	1.3	6
207	Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 229-234.	0.3	5
208	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. <i>Lancet</i> , The, 2012, 380, 572-580.	13.7	1,937
209	Costâ€“effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012, 13, 1405-1417.	1.3	17
210	Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. <i>Pharmacogenomics</i> , 2012, 13, 1239-1245.	1.3	11
211	The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 1068-1069.	2.4	4
212	Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. <i>Clinical Cancer Research</i> , 2012, 18, 4526-4537.	7.0	48
213	Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2610-2612.	3.8	9
214	Variation at <i>GLCCI1</i> and <i>FCER2</i> : one step closer to personalized asthma treatment. <i>Pharmacogenomics</i> , 2012, 13, 243-245.	1.3	12
215	Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci. <i>American Journal of Human Genetics</i> , 2012, 90, 410-425.	6.2	239
216	Meta-analysis of Dense Gene-centric Association Studies Reveals Common and Uncommon Variants Associated with Height. <i>American Journal of Human Genetics</i> , 2012, 90, 1116-1117.	6.2	0

#	ARTICLE	IF	CITATIONS
217	Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 606-614.	3.8	22
218	An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 767-772.	3.8	15
219	Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study. <i>Pediatric Allergy and Immunology</i> , 2012, 23, 529-536.	2.6	24
220	Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. <i>Clinica Chimica Acta</i> , 2011, 412, 2063-2069.	1.1	33
221	Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. <i>Atherosclerosis</i> , 2011, 217, 458-464.	0.8	38
222	FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1546-1552.	5.7	65
223	Uncontrolled asthma at age 8: The importance of parental perception towards medication. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 462-468.	2.6	43
224	Limited agreement between current and long-term asthma control in children: the PACMAN cohort study. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 776-783.	2.6	16
225	Biomarkers of therapy responsiveness in asthma: pitfalls and promises. <i>Clinical and Experimental Allergy</i> , 2011, 41, 615-629.	2.9	42
226	Pharmacogenetics: From Bench to Byte” An Update of Guidelines. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 662-673.	4.7	869
227	Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. <i>Pharmacogenomics Journal</i> , 2011, 11, 72-80.	2.0	16
228	Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. <i>European Heart Journal</i> , 2011, 32, 1909-1917.	2.2	86
229	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. <i>American Journal of Human Genetics</i> , 2011, 88, 6-18.	6.2	122
230	From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. <i>International Journal of Clinical Pharmacy</i> , 2011, 33, 3-9.	2.1	19
231	Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1064-1072.	1.9	48
232	CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel. <i>Pharmacogenomics</i> , 2011, 12, 141-144.	1.3	5
233	Implementation of pharmacogenetics in clinical practice is challenging. <i>Pharmacogenomics</i> , 2011, 12, 1231-1233.	1.3	8
234	Asthma medication use in infancy: determinants related to prescription of drug therapy. <i>Family Practice</i> , 2011, 28, 377-384.	1.9	6

#	ARTICLE	IF	CITATIONS
235	Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 208-214.	1.7	8
236	Asthma Symptoms in Pediatric Patients: Differences throughout the Seasons. <i>Journal of Asthma</i> , 2011, 48, 694-700.	1.7	14
237	Pharmacogenetics and the Pharmaceutical Industry. <i>Current Pharmaceutical Design</i> , 2010, 16, 238-244.	1.9	7
238	Methodological and statistical issues in pharmacogenomics. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 161-166.	2.4	26
239	A systematic review of effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010, 11, 989-1002.	1.3	26
240	Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 991-999.	1.9	6
241	High agreement between parental reported inhaled corticosteroid use and pharmacy prescription data. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1199-1203.	1.9	16
242	Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 766-774.	1.5	10
243	Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 375-378.	1.4	3
244	Pharmacogenetic interactions between <i>ABCB1</i> and <i>SLCO1B1</i> tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. <i>Pharmacogenomics</i> , 2010, 11, 1065-1076.	1.3	42
245	Statin Prescribing in the Elderly in the Netherlands. <i>Drugs and Aging</i> , 2010, 27, 589-596.	2.7	34
246	Asthma Therapy During the First 8 Years of Life: A PIAMA Cohort Study. <i>Journal of Asthma</i> , 2010, 47, 209-213.	1.7	11
247	Pharmacogenetics of Anti-Inflammatory Therapy in Asthma: Corticosteroids and Leukotriene Antagonists. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2010, 9, 267-275.	1.1	1
248	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. <i>Pharmacogenomics</i> , 2009, 10, 1687-1695.	1.3	131
249	Systems biology in pharmacogenomic research: the way to personalized prescribing?. <i>Pharmacogenomics</i> , 2009, 10, 971-981.	1.3	19
250	Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 158-164.	1.4	17
251	Determinants of DNA yield and purity collected with buccal cell samples. <i>European Journal of Epidemiology</i> , 2009, 24, 677-682.	5.7	23
252	Systematic Review of Pharmacogenetic Warfarin Dosing. <i>Journal of General Internal Medicine</i> , 2009, 24, 1171.	2.6	1

#	ARTICLE	IF	CITATIONS
253	Reasons for non-response in observational pharmacogenetic research. <i>Pharmacoeconomics and Drug Safety</i> , 2009, 18, 665-671.	1.9	9
254	Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort. <i>Pharmacogenomics</i> , 2009, 10, 1351-1361.	1.3	33
255	Pharmacogenomic insights into treatment and management of statin-induced myopathy. <i>Genome Medicine</i> , 2009, 1, 120.	8.2	17
256	Genetic determinants of response to statins. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 977-983.	1.5	17
257	The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 338-344.	1.5	20
258	Interaction between the Gly460Trp β -adducin gene variant and diuretics on the risk of myocardial infarction. <i>Journal of Hypertension</i> , 2009, 27, 61-68.	0.5	29
259	Clinical impact of adducin polymorphism. <i>Journal of Hypertension</i> , 2009, 27, 1328-1329.	0.5	0
260	Pharmacogenetics of cardiovascular drug therapy. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2009, 6, 55-65.	1.0	7
261	Pharmacogenomic importance of pravastatin. <i>Pharmacogenomics</i> , 2008, 9, 1207-1210.	1.3	4
262	Are there interactions between the Gly460Trp β -adducin gene variant and the use of diuretics?. <i>Personalized Medicine</i> , 2008, 5, 117-121.	1.5	1
263	Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR Tj ETQq1 1 0.784314 rgBT /Overlook preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 651-656.	1.5	34
264	Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 631-636.	1.5	11
265	Epistatic Effect of Cholesteryl Ester Transfer Protein and Hepatic Lipase on Serum High-Density Lipoprotein Cholesterol Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2680-2687.	3.6	25
266	Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT) study. <i>American Heart Journal</i> , 2007, 153, 54-58.	2.7	25
267	Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). <i>Acta Cardiologica</i> , 2006, 61, 327-331.	0.9	28
268	A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 287-293.	1.5	25
269	Pharmacogenetics of response to statins: Where do we stand?. <i>Current Atherosclerosis Reports</i> , 2005, 7, 204-208.	4.8	23
270	Demographic, Environmental, and Genetic Predictors of Metabolic Side Effects of Hydrochlorothiazide Treatment in Hypertensive Subjects. <i>American Journal of Hypertension</i> , 2005, 18, 1077-1083.	2.0	29

#	ARTICLE	IF	CITATIONS
271	Pharmacogenetics in health-care practice. International Journal of Clinical Pharmacy, 2004, 26, 253-255.	1.4	5
272	Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness. Journal of Clinical Epidemiology, 2004, 57, 237-242.	5.0	5
273	Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis, 2004, 175, 377-379.	0.8	21
274	Adherence to and dosing of ??-hydroxy-??-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics and Genomics, 2003, 13, 219-223.	5.7	36
275	The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics and Genomics, 2002, 12, 647-653.	5.7	21
276	Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis, 2002, 163, 213-222.	0.8	71
277	Drug-Induced Lipid Changes. Drug Safety, 2001, 24, 443-456.	3.2	100
278	The association between antihypertensive drug therapies and plasma lipid levels in the general population. Journal of Human Hypertension, 2001, 15, 701-705.	2.2	11
279	Pharmacogenetics and the Role of the Pharmacist. Journal of Pharmaceutical Finance, Economics and Policy, 2001, 11, 143-150.	0.9	2
280	Immunotherapy for Upper Airway Disease Generates IL-10-Producing KLRG1 <sup>+</sup> ILC2s that are Associated with Clinical Benefit. SSRN Electronic Journal, 0, , .	0.4	0